Introduction
============

Leukocytes spend the majority of their life circulating into blood and lymphoid vessels until local environmental cues claim their presence into sites of immune response. The capability to resist to extreme hemodynamic stress and turbulence within high diameter vessels and to avoid cell--cell aggregation in the circulation are prerequisites to allow leukocytes to embrace blood and lymph vessels like highways leading to the widest possible distribution of the immune system in the organism. However, there are adverse implications. Indeed, nothing can be more difficult for a cell than trying to stop its motion under the frantic flow conditions generated by the circulation. These conditions are important to regulate cell trafficking, by imposing physical thresholds to leukocyte recruitment, with the flow itself providing mechano-chemical signals regulating leukocyte trafficking (Zhu et al., [@B75]; McEver and Zhu, [@B43]). But at the end, to fulfill their duties, leukocytes must be able to counteract the pushing force generated by the flow, arresting on the surface of endothelial cells and transmigrating into tissues. Everything must be done within few second or less to cope with the timing imposed by flow dynamics. In the past two decades consistent efforts have been made to understand the physiology and molecular bases of the leukocyte recruitment process and a general, widely validated, model describing the entire process has been generated (Laudanna and Alon, [@B36]; Ley et al., [@B39]; Alon and Shulman, [@B2]). A critical step in this process is the transition from rolling to stable arrest, which is the moment when leukocytes become fully resistant to the flow and definitively stop on the vessel wall. This critical phase is mediated by a family of leukocyte-expressed cytoskeleton-regulated adhesive receptors, called integrins (Takada et al., [@B65]). Integrins are capable of establishing sudden and very stable adhesive interactions with endothelial ligands expressed on the inner surface of the vessels and belonging to the immunoglobulin superfamily. The strong adhesive interaction between integrins and their ligands supporting arrest of circulating leukocytes is, *de facto*, the primum movens of the immune response.

Integrins basally interact with the ligand with rather low affinity. To increase binding efficiency integrins must undergo dramatic structural and topological modifications consisting of extensive conformational changes leading to increased affinity for the ligand, along with concurrent spatial rearrangement on the cell plasma membrane. This phenomenon is globally indicated as integrin activation and is mandatory to rapid arrest of circulating cells. The step of integrin activation is finely regulated to allow diversity of leukocyte recruitment, but its most distinguishing property is the speediness. This implies the existence of environmental factors capable of activating integrins with corresponding dynamics. The original discovery of a role for a PTX-sensitive Gai-protein linked signaling in regulation of lymphocyte homing (Bargatze and Butcher, [@B5]) prompted the search for microvessel-presented agonists capable of triggering integrin-dependent arrest within seconds. It is now established that arrest chemokines, a subgroup of chemotactic cytokines capable of rapid integrin activation (Rot and von Andrian, [@B54]; Bromley et al., [@B9]), are the most potent physiological activator of leukocyte adhesiveness. They do that by triggering complex signaling transduction mechanisms leading to extremely rapid activation of integrins and, ultimately, of adhesion. In this context, the most studied and best-known signaling events are represented by the signaling networks regulated by the small GTP binding proteins of the ras-like rap and rho family (Caron, [@B12]; Scheele et al., [@B58]; Tybulewicz and Henderson, [@B67]). More than 670 interacting proteins belong to these signaling networks, including upstream regulators and downstream effectors (see <http://www.pathwaycommons.org/pc/>), with specific sub-sets of these interactions devoted to modulation of leukocyte integrin activation and dependent adhesion. Here we will summarize the available data about the signaling mechanisms triggered by arrest chemokines and controlling rapid integrin affinity transitions critical to leukocyte arrest.

Integrin-Dependent Adhesion: An Overview
========================================

At least two distinct modalities of integrin activation are known, namely conformational changes, leading to increased affinity, and lateral mobility leading to increased valency, both concurrently enhancing cell avidity (adhesiveness; Arnaout et al., [@B3]). The most detailed information about integrin structural rearrangement during affinity up-regulation in leukocytes comes from studies of LFA-1. Recent structural and biophysical data predict that LFA-1 exists in at least three conformational states, which differ both in their overall extension over the plasma membrane as well as in the arrangement of their headpiece (Carman and Springer, [@B11]; Luo et al., [@B41]; Springer and Dustin, [@B61]; Figure [1](#F1){ref-type="fig"}). Inside-out signaling events trigger integrins to undergo a dramatic transition from a bent low-affinity conformation to an extended intermediate-affinity to a high-affinity conformation, characterized by a complete opening of the ligand-binding pocket (Nishida et al., [@B49]; Luo et al., [@B41]). Extended β2 integrin conformations with high topographical availability of the ligand-binding headpiece but low affinity for the ligand have been also postulated (Salas et al., [@B55], [@B56]). This extended but low/intermediate-affinity conformation may increase the capability of LFA-1 to mediate rolling on ICAM-1 upon selectin triggering (Chesnutt et al., [@B13]; Zarbock et al., [@B74]; Miner et al., [@B45]).

![**Integrin affinity triggering**. The diagram refers to the LFA-1 affinity-triggering model. Shown is the dynamic equilibrium between three conformers displaying low-, low/intermediate-, and high-affinity for ICAM-1. The progressive extension of the heterodimer is accompanied by increasing topological availability of the I-domain and I-like domain (in yellow), which are involved in ligand binding with increasing affinity.](fimmu-03-00127-g001){#F1}

It is important to emphasize that low-, intermediate-, and high-affinity integrins likely represent discrete, reversible, states in a continuum of integrin conformational changes (Figure [1](#F1){ref-type="fig"}). Thus, the correct interpretation of the integrin activation process is a dynamic equilibrium between different conformers, corresponding to inside-out triggered conformational changes of the heterodimer displaying increasing affinity (binding energy) for the ligand (Carman and Springer, [@B11]; Shamri et al., [@B60]). Importantly, it has been demonstrated that LFA-1 integrin conformational changes are critical to the *in vivo* arrest of lymphocytes on the high endothelial venules (HEV) of secondary lymphoid organs (Giagulli et al., [@B25]). Thus, modulation of integrin affinity is now recognized as the critical step to leukocyte arrest *in vivo*.

Notably, integrins may undergo not only rapid inside-out regulation of affinity but also structural stabilization transmitted to the cytosolic tail by the bound ligand. The two processes are believed to cooperate to enhance integrin-mediated adhesiveness in a rapid and reversible manner. For instance, the induction of conformational changes transmitted to the cytosolic tail of the LFA-1 heterodimer upon ICAM-1 binding (Kim et al., [@B34]) may have a role in stabilizing leukocytes arrest under flow. However, this bi-directional regulation of integrin binding may be insufficient to support prolonged shear-resistant firm adhesions, and so post ligand occupancy events leading to integrin anchorage to the cytoskeleton are apparently required to further increase mechanical stability of individual ligand-occupied integrins (Cairo et al., [@B10]). Notably, these phenomena can be concurrent to the other modality of integrin activation, that is valency up-regulation. Heterodimer lateral mobility and valency increase is also regulated by interaction with the cytoskeleton, which could behave as mobility restrain (Stewart et al., [@B62]; van Kooyk and Figdor, [@B68]; Svensson et al., [@B63]; Bakker et al., [@B4]). Thus, it seems that, to stabilize the adhesion, a shuttling between restraining and stabilizing cytoskeletal proteins must occur. Valency up-regulation can be directly triggered by chemokine signaling leading to formation of multivalent complex on the plasma membrane. This may have a role under specific conditions by facilitating the encountering of activated mobile integrins with the immobilized ligand (Constantin et al., [@B14]). Furthermore, increase of integrin valency may also contribute to the initiation of outside-in signaling cascades, leading to the efficient recruitment of protein tyrosine kinases (PTKs; Berton et al., [@B7]) and the initiation of the full repertoire of outside-in signaling pathways leading to adhesion stabilization. Notably, it has been shown that lacking of integrin signaling capability leads to accelerated leukocyte detachment (Giagulli et al., [@B24]). Thus, chemoattractant-triggered inside-out and integrin-initiated outside-in signaling events concurrently cooperate to increase integrin affinity for the ligand and to stabilize and prolong the arrest of circulating leukocytes.

The Role of rap and rho in Integrin Affinity Modulation
=======================================================

A plethora of signaling events have been implicated in the regulation of various kinetic aspects of integrin-mediated adhesion. Overall, at least 65 signaling proteins are possibly involved in the regulation of integrin-mediated adhesion by chemoattractants and other agonists (Table [1](#T1){ref-type="table"}). However, it is important to emphasize that only a subset of this group of signaling molecules has been validated under physiological conditions significant to chemokine-modulated rapid arrest of circulating leukocytes. These conditions, which we may call "*the four criteria*," should include: (a) evaluation of signaling events in primary leukocytes; (b) evaluation of adhesion under flow conditions; (c) measurement of rapid kinetics of adhesion triggering (seconds or less); and (d) direct detection of heterodimer conformational changes. The rationale for adopting such criteria is based of the following considerations: (a) Signaling studies should be always accurately contextualized, by first focusing on physiological, standard, conditions followed by comparative analysis in more specific contexts. For instance, neoplastic leukocyte cell lines are not appropriate models of physiologic leukocyte adhesion since the neoplastic transformation may alter the signaling machinery with respect to normal primary cells, thus affecting response to the agonists and data interpretation. (b) Flow is the natural condition during cell recruitment by generating a shear stress, which imposes a mechanistic threshold to adhesion activation; thus, the efficacy of signaling events in regulating leukocyte arrest should be always challenged by applying flow conditions. (c) Integrin activation under-flow occurs in the range of seconds or less (likely milliseconds); thus, to correlate signaling events to integrin activation relevant to leukocyte recruitment, the kinetics of the two events must be coherent. Such kinetics cannot be studied in static assays. (d) As stated above, integrin-mediated adhesion is a general concept. To precisely assess whether a signaling event specifically regulates integrin conformational changes leading to affinity increase it is necessary to be able to directly detect integrin structural rearrangements by means of soluble ligand-binding assays or reporter monoclonal antibodies detecting activation epitopes. *These four criteria should be always satisfied in order to correlate signaling events to affinity triggering controlling leukocyte rapid arrest in physiological contexts*. Unfortunately, these experimental criteria are not systematically applied in the literature and this may affect the correct interpretation of the regulatory role of pro-adhesive signal transduction events.

###### 

**The signaling molecules involved in the regulation of integrin-dependent adhesion in leukocytes**.

  HGNC-ID     GI-ID    Aliases                                        Approved names                                                                               Chromosome
  ----------- -------- ---------------------------------------------- -------------------------------------------------------------------------------------------- ---------------
  *ACTN1*     87                                                      Actinin, alpha 1                                                                             14q24.1
  *APBB1IP*   54518    INAG1, RIAM                                    Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein          10p12.1
  *ARF1*      375                                                     ADP-ribosylation factor 1                                                                    1q42.13
  *ARF6*      382                                                     ADP-ribosylation factor 6                                                                    14q21.3
  *CDC42*     998      G25K, CDC42Hs                                  Cell division cycle 42 (GTP binding protein, 25 kD)                                          1p36.1
  CYTH1       9267     B2-1, D17S811E, PSCD1                          Cytohesin-1; pleckstrin homology, Sec7 and coiled-coil domains 1                             17q25
  *DOCK2*     1794     KIAA0209                                       Dedicator of cytokinesis 2                                                                   5q35.1
  *FERMT3*    83706    URP2, KIND3, MIG2B, MGC10966, MIG-2, UNC112C   Kindlin-3                                                                                    11q13.1
  *FGR*       2268     c-fgr, p55c-fgr                                Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog                                1p36.2-p36.1
  *FYB*       2533     SLAP-130, ADAP                                 FYN binding protein (FYB-120/130)                                                            5p13.1
  *HCK*       3055     JTK9                                           Hemopoietic cell kinase                                                                      20q11-q12
  *HRAS*      3265                                                    v-Ha-ras Harvey rat sarcoma viral oncogene homolog                                           11p15.5
  *ILK*       3611                                                    Integrin-linked kinase                                                                       11p15.4
  *PIK3AP1*   118788   BCAP, FLJ35564                                 Phosphoinositide-3-kinase adaptor protein 1                                                  10q24.2
  *PIK3C2A*   5286     PI3K-C2alpha                                   Phosphoinositide-3-kinase, class 2, alpha polypeptide                                        11p15.5-p14
  *PIK3C2B*   5287     C2-PI3K, PI3K-C2beta                           Phosphoinositide-3-kinase, class 2, beta polypeptide                                         1q32
  *PIK3C2G*   5288                                                    Phosphoinositide-3-kinase, class 2, gamma polypeptide                                        12p12
  *PIK3C3*    5289     Vps34                                          Phosphoinositide-3-kinase, class 3                                                           18q12.3
  *PIK3CA*    5290                                                    Phosphoinositide-3-kinase, catalytic, alpha polypeptide                                      3q26.3
  *PIK3CB*    5291                                                    Phosphoinositide-3-kinase, catalytic, beta polypeptide                                       3q21-qter
  *PIK3CD*    5293     p110D                                          Phosphoinositide-3-kinase, catalytic, delta polypeptide                                      1p36.2
  *PIK3CG*    5294                                                    Phosphoinositide-3-kinase, catalytic, gamma polypeptide                                      7q
  *PIK3R1*    5295     GRB1, p85-ALPHA                                Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha)                                  5q13.1
  *PIK3R2*    5296     P85B                                           Phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta)                                   19q13.2-q13.4
  *PIK3R3*    8503                                                    Phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma)                                 1p34.1
  *PIK3R4*    30849    VPS15, P150                                    Phosphoinositide-3-kinase, regulatory subunit 4, p150                                        3q22.1
  *PIK3R5*    23533    P101-PI3K                                      Phosphoinositide-3-kinase, regulatory subunit 5, p101                                        17p13.1
  *PIP5K1C*   23396    PIP5Kgamma, KIAA0589                           Phosphatidylinositol-4-phosphate 5-kinase, type I, gamma, 87 kD isoform                      19
  *PIP5K1C*   23396    PIP5Kgamma                                     Phosphatidylinositol-4-phosphate 5-kinase, type II, gamma, 90 kD isoform                     19
  *PKD1*      5310     PBP                                            Polycystic kidney disease 1 (autosomal dominant)                                             16p13.3
  *PLCB1*     23236    KIAA0581                                       Phospholipase C, beta 1 (phosphoinositide-specific)                                          20p12
  *PLCB2*     5330                                                    Phospholipase C, beta 2                                                                      15q15
  *PLCB3*     5331                                                    Phospholipase C, beta 3 (phosphatidylinositol-specific)                                      11q13
  *PLCB4*     5332                                                    Phospholipase C, beta 4                                                                      20p12
  *PLCE1*     51196    KIAA1516, PLCE                                 Phospholipase C, epsilon 1                                                                   10q23
  *PLCG1*     5335     PLC148, PLC-II, PLCgamma1                      Phospholipase C, gamma 1                                                                     20q12-q13.1
  *PLCG2*     5336                                                    Phospholipase C, gamma 2 (phosphatidylinositol-specific)                                     16q24.1
  *PLD1*      5337                                                    Phospholipase D1, phosphatidylcholine-specific                                               3q26
  *PRKAA1*    5562     AMPKa1                                         Protein kinase, AMP-activated, alpha1 catalytic subunit                                      5p12
  *PRKAA2*    5563     AMPK                                           Protein kinase, AMP-activated, alpha2 catalytic subunit                                      1p31
  *PRKAB1*    5564     AMPK beta 1                                    Protein kinase, AMP-activated, beta 1 non-catalytic subunit                                  12q24.1-24.3
  *PRKAB2*    5565     AMPK beta 2                                    Protein kinase, AMP-activated, beta 2 non-catalytic subunit                                  1q21.2
  *PRKACA*    5566                                                    Protein kinase, cAMP-dependent, catalytic, alpha                                             19p13.1
  *PRKACB*    5567                                                    Protein kinase, cAMP-dependent, catalytic, beta                                              1p36.1
  *PRKAG1*    5571                                                    Protein kinase, AMP-activated, gamma 1 non-catalytic subunit                                 12q12-q14
  *PRKAG2*    51422    AAKG, AAKG2                                    Protein kinase, AMP-activated, gamma 2 non-catalytic subunit                                 7q35-q36
  *PRKAG3*    53632                                                   Protein kinase, AMP-activated, gamma 3 non-catalytic subunit                                 2
  *PRKAR1A*   5573                                                    Protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1)   17q23-q24
  *PRKAR1B*   5575                                                    Protein kinase, cAMP-dependent, regulatory, type I, beta                                     7pter-p22
  *PRKAR2A*   5576                                                    Protein kinase, cAMP-dependent, regulatory, type II, alpha                                   3p21.3-p21.2
  *PRKAR2B*   5577                                                    Protein kinase, cAMP-dependent, regulatory, type II, beta                                    7q31-qter
  *PRKCZ*     5590     PKC2                                           Protein kinase C, zeta                                                                       1p36.33-p36.2
  *RAC1*      5879     TC-25, p21-Rac1                                Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)      7p22
  *RAP1A*     5906     KREV-1, SMGP21                                 RAP1A, member of RAS oncogene family                                                         1p13.3
  *RASGRP1*   10125    CalDAG-GEFII, RASGRP, V                        RAS guanyl releasing protein 1 (calcium and DAG-regulated)                                   15q15
  *RASSF5*    83593    RAPL, Maxp1, NORE1, MGC10823,                  Ras association (RalGDS/AF-6) domain family 5                                                1q31
  *RHOA*      387      RhoA, Rho12, RHOH12                            Ras homolog gene family, member A                                                            3p21.3
  *RHOH*      399      RhoH, TTF                                      Ras homolog gene family, member H                                                            4p13
  *SRC*       6714     ASV, c-src                                     v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)                            20q12-q13
  *SKAP1*     8631     SKAP55                                         src kinase associated phosphoprotein 1                                                       17q21.32
  *STK4*      6789     MST1, KRS2, YSK3                               Serine/threonine kinase 4                                                                    20q11.2-q13.2
  *SYK*       6850                                                    Spleen tyrosine kinase                                                                       9q22
  *SWAP70*    23075    KIAA0640, SWAP-70, HSPC321                     SWAP switching B cell complex 70 kD subunit                                                  11p15
  *TLN1*      7094     ILWEQ                                          Talin-1                                                                                      9p23-p21
  *VAV1*      7409                                                    vav 1 oncogene                                                                               19p13.2

*The table lists the 65 signaling proteins reported to date to be involved in regulation of integrin-mediated adhesion in different experimental contexts. Notably, few of them have been validated under experimental conditions satisfying the *four criteria* (see text). Shown are HGNC and Gi protein IDs, alias, full names, and chromosome localization*.

The intracellular signaling cascade from arrest chemokines, such as CCL19, CCL21, or CXCL12, to integrin affinity modulation is still incompletely understood. The two most studied and validated signaling mechanisms activated by arrest chemokines and leading to up-regulation of integrin affinity, especially in the context of the β2 integrin LFA-1, are related to signaling delivered by the small GTP binding proteins of the rap and rho family. Both rap and rho are capable of activating a variety of downstream effectors and are, in turn, activated by several upstream regulators (Caron, [@B12]; Scheele et al., [@B58]; Tybulewicz and Henderson, [@B67]). However, in the specific context of integrin activation by arrest chemokines, rap and rho regulate restricted signaling modules devoted to the specific control of integrin affinity.

The role of the rap isoform Rap1A in integrin activation by arrest chemokines has been extensively studied and it is now clearly demonstrated that Rap1A regulates rapid integrin-dependent adhesion either in the context of the β2 integrin LFA-1 as well as β1 integrin VLA-4 (Duchniewicz et al., [@B18]). Rap1A was shown to control arrest of rolling lymphocytes as well as *in vivo* homing to secondary lymphoid organs (Ebisuno et al., [@B19]). Rap1A is activated by arrest chemokines by means of an upstream signaling mechanism involving phospholipase C (PLC). Indeed, ligation of chemokine receptors, and more in general of all chemoattractants Gαi-protein coupled receptors (GPCRs), results in rapid intracellular calcium influx and activation of PLC (particularly of the β isoforms), which leads to generation of inositol-1,4,5-trisphosphate (IP~3~, which further increases intracellular calcium from intracellular stores) and diacylglycerol (DAG). Calcium and DAG are, in turn, critical to activate the rap-specific guanine-nucleotide-exchange factor (GEF) calcium- and DAG-regulated GEF (CALDAG--GEF), also known as RAPGEF2; Crittenden et al., [@B15]; Bergmeier et al., [@B6]), which, ultimately, activates Rap1A. The role of other rap GEFs, such as C3G (RAPGEF1) and EPAC (RAPGEF3), in the context of chemokine signaling leading to integrin affinity regulation, is still not addressed. Once activated, Rap1A transmits downstream signals through different effectors, including RAPL (RASSF5; Ebisuno et al., [@B19]) RIAM (APBB1IP; Lafuente and Boussiotis, [@B35]), MST1 (STK4; Katagiri et al., [@B31]), SKAP55 (SKAP1), and ADAP (FYB; Menasche et al., [@B44]; see below). Although these signaling events lead to pro-adhesive events, the role of these signaling molecules in chemokine-triggered integrin affinity regulation mediating leukocyte arrest is still not clarified. Notably, in monocytes, PLC-mediated calcium signaling is required for induction of high-affinity α~4~-integrin ligation and monocyte arrest (Hyduk et al., [@B28]). However, an important recent study showed that Rap1A is, *de facto*, unable to modulate LFA-1 affinity conformeric transitions, thus apparently implicating Rap1A and its effectors in adhesive events other than integrin affinity regulation (Ebisuno et al., [@B19]), such as removal of cytosolic constrains or post-binding stabilization (Ebisuno et al., [@B19]).

A role for the rho isoform RhoA in chemoattractant-induced rapid integrin activation was originally suggested in the context of the β1 integrin VLA-4 (Laudanna et al., [@B37]), although those studies did not fully satisfied the *four criteria* described above. However, more recently it was clearly demonstrated that, under physiological conditions, RhoA and Rac1 mediate LFA-1 affinity triggering by arrest chemokines (Giagulli et al., [@B25]; Bolomini-Vittori et al., [@B8]). The role of rho-specific GEF in mediating RhoA and/or Rac1 activation by arrest chemokines is still not fully clarified, although recent data show that DOCK2 (dedicator of cytokinesis 2; Garcia-Bernal et al., [@B22]) and VAV1 (Gakidis et al., [@B20]; Garcia-Bernal et al., [@B23]) may participate to leukocyte integrin affinity modulation. In other studies, however, VAV1 seems to have a negative regulatory role on VLA-4 affinity regulation (Garcia-Bernal et al., [@B21]). Once activated, RhoA and Rac1 activate a variety of downstream effectors, but only few of them have been tested as effectors to integrin affinity modulation by chemokines. In this context, PLD1 and the 87 kD isoform of PIP5K1C have been demonstrated to play a critical role in LFA-1 affinity modulation by chemokines. Thus, RhoA- and Rac1-activated PLD1 was shown to control chemokine triggering of LFA-1 extensions corresponding to both intermediate and high affinity states. Moreover, by leading to plasma membrane accumulation of phosphatidic acid, PLD1 mediates the activation of PIP5K1C. However, PIP5K1C was shown to control LFA-1 affinity triggering by chemokines in a conformer-selective manner, with transition from intermediate to high affinity, but not from low to intermediate affinity, states controlled by the kinase activity of PIP5K1C (Bolomini-Vittori et al., [@B8]). These findings have important implication for our comprehension of LFA-1 affinity modulation. Indeed, these data show that the complete LFA-1 conformeric transition from a bent to a fully extended structure is accurately controlled at the level of inside-out signal transduction, even in absence of ICAM-1 interaction with LFA-1 in extended intermediate affinity state (Bolomini-Vittori et al., [@B8]). Thus, arrest chemokines are fully competent to trigger a complete LFA-1 affinity transition supporting arrest of rolling leukocytes. In contrast, in the context of rho-mediated LFA-1 affinity modulation, CDC42 was shown to negatively regulate LFA-1 affinity triggering by chemokines, thus establishing a sharp dichotomy with respect to the other two most homologous rho small GTPases (Bolomini-Vittori et al., [@B8]). CDC42 seems to affect LFA-1-mediated adhesion by blocking PIP5K1C activation (Bolomini-Vittori et al., [@B8]). Moreover, it was recently shown that activated CDC42 also inhibits Rap1A activation by chemoattractants (Kempf et al., [@B32]), thus highlighting a complex negative regulatory role for CDC42 in adhesion-de-adhesion cycling. Overall, arrest chemokines regulate integrin-dependent rapid adhesion by means of two main signaling modules: (a) the rap-module, likely including PLC, CALDAG--GEF, Rap1A, RAPL, RIAM, STK4, SKAP55, and ADAP; (b) the rho-module likely including at least DOCK2, VAV1, RhoA, Rac1, CDC42, PLD1, and PIP5K1C.

Deep in the Modules: The Very Downstream Events
===============================================

Several cytosolic proteins, either or not of cytoskeletal nature, have been shown to directly interact with the integrin cytoplasmic tails of both alpha and beta chains and to regulate integrin functionality (Alon, [@B1]; Hogg et al., [@B27]). The most proximal to the heterodimer (downstream) signaling event leading to integrin affinity triggering is likely represented by interaction with actin-binding proteins. Among them, Talin-1 (TLN1) is the most studied actin-binding protein implicated in triggering integrin affinity up-regulation. Talin-1 is an anti-parallel homodimer. The F3 region of the head domain interacts with the cytoplasmic tail of the β chain of platelet gpIIb/IIIa (α~IIb~β~3~-integrin) and triggers the transition to an increased affinity state (Tadokoro et al., [@B64]). The idea that the head of Talin-1 wedges between the α and β cytoplasmic tails of integrins (Tadokoro et al., [@B64]) is consistent with the observation that the α and β tails move apart during LFA-1 activation (Kim et al., [@B34]). At present, it is not clear whether Talin-1 controls the triggering of LFA-1 to its intermediate- or high-affinity state. Other actin-binding proteins, such as α-actin in and L-plastin have been also suggested to mediate LFA-1 affinity transition (Jones et al., [@B30]; Sampath et al., [@B57]). More recently, Kindlin-3 (FERMT3) and Cytohesin-1 (CYTH1), a GEF for ADP-ribosylation factor 6 (Arf6), have been suggested to mediate LFA-1 affinity activation (Weber et al., [@B71]; Manevich-Mendelson et al., [@B42]; Moser et al., [@B48]; Lefort et al., [@B38]), although not always under fully physiological conditions. Furthermore, the Rap1A effectors RAPL and RIAM have been shown to behave as direct integrin-binding proteins regulating integrin activation. RAPL was shown to directly bind the cytosolic tail of LFA-1 alpha chain (CD11a), but this was related to stabilization events and not to affinity triggering (Ebisuno et al., [@B19]). On the other hand, RIAM was suggested to directly bind Talin-1, thus potentially bridging Rap1A to Talin-1-controlled integrin affinity triggering. However, the role of these Rap1A effectors in affinity modulation by chemokines in conditions satisfying the *four criteria* is still not described. Thus, at present, is not clear how the rap-module may control the last steps of integrin activation. A link between the rho-module and the very downstream events of integrin affinity activation demonstrated under conditions satisfying the *four criteria* is also lacking. However, it is possible to speculate. Indeed, Talin-1, Kindlin-3, Cytohesin-1, and RIAM possess FERM and PH domains critical to support their interaction with plasma membrane phospholipids. Thus, it is likely that the lipid kinase activity of rho/PLD1-activated PIP5K1C, by increasing the local membrane concentration of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2), may trigger the membrane translocation, activation, and direct integrin interaction of these regulatory proteins. Notably, a functional link between Cytohesin-1 and RhoA in the context of LFA-1 affinity triggering was recently described (Quast et al., [@B53]). Theoretically, since the 90 kD isoform of PIP5K1C (also activated by RhoA) directly interacts with Talin-1 (Di Paolo et al., [@B17]), it is also possible that this PIP5K1C isoform physically bridges directly RhoA to integrin affinity activation, independently of PtdIns(4,5)P2 lipid kinase activity. However, a recent report, although obtained under condition not satisfying the *four criteria*, seems to challenge this hypothesis (Wernimont et al., [@B72]).

Do rap and rho Talk Each Other?
===============================

Overall, in the context of signal transduction networks controlling chemokine-triggered integrin activation, rap and rho small GTPases may orchestrate the signaling activity of at least 18 signaling proteins and including PLC, CALDAG--GEF, Rap1A, RAPL, RIAM, STK4, SKAP55, ADAP, DOCK2, VAV1, RhoA, Rac1, CDC42, PLD1, PIP5K1C, Talin-1, Kindlin-3, and Cytohesin-1. It is quite likely that other signaling players will be discovered, especially accounting for context-specificity (see below). Moreover, we still need testing the role of some of these molecules under physiological condition, fully satisfying the *four criteria* proposed above. However, it is unquestionable that rap- and rho-modules represent, at present, our best paradigm of integrin affinity regulation by chemokines. An obvious question is whether these two signaling modules display concurrency and if they work in parallel of serially. The concept of "concurrency" is derived from computer science, where computation of contemporary events often occurs (D'Ambrosio et al., [@B16]). Thus, in a concurrent model of integrin activation, the final state of the system (fully extended conformation leading to high affinity for the ligand) is achieved only if the regulatory signaling events are delivered simultaneously and integrated at quantitative level. The simple fact that chemokines trigger simultaneously the activation of rap and rho small GTPases with kinetics consistent with rapid integrin activation, clearly suggests that the system displays concurrency (although we are still very far from a quantitative view of the process). This conclusion is supported by recent findings showing cooperation between rap and rho in controlling integrin activation (Vielkind et al., [@B69]; Kim et al., [@B33]; Li et al., [@B40]). An even more interesting question concerns the possibility that rap and rho not only cooperate but also directly influence each other biochemical activity, which corresponds to ask whether rap and rho act in parallel or serially. Although not yet verified in conditions satisfying the *four criteria*, data from the literature may suggest interesting possibilities. Indeed, RhoA and Rac1 activate PLC isoforms, including the PLCβ, PLCΓ, and PLCε (Thodeti et al., [@B66]; Illenberger et al., [@B29]; Wing et al., [@B73]; Piechulek et al., [@B52]; Seifert et al., [@B59]; Walliser et al., [@B70]; Guo et al., [@B26]) which, in turn, could determine the activation of Rap1A through CALDAG--GEF. Notably, the lipid kinase activity of PIP5K1C itself may contribute to Rap1A activation by increasing the local concentration of PtdIns(4,5)P2, which, in turn, is substrate of PLCs leading to activation of CALDAG--GEF and, ultimately, of Rap1A. Furthermore, it was recently shown that PLD1 activity is required to Rap1A plasma membrane translocation and activation (Mor et al., [@B47]), thus establishing a strong functional link between rho signaling activity and rap activation. Finally, as reported above, CDC42 was recently shown to inhibit Rap1A activation (measured as GTP bound state) (Kempf et al., [@B32]). Altogether, these data suggest that Rap1A signaling activity may be directly influenced by rho, thus controlling a critical arm of the global module of integrin activation, possibly devoted to aspects of integrin-dependent adhesion other than conformational changes and affinity up-regulation (Figure [2](#F2){ref-type="fig"}).

![**The rap- and rho-modules of integrin affinity modulation by chemokines**. The diagram mainly reports data regarding LFA-1 affinity triggering. Dotted lines refer to hypothetic effects. Red lines emphasize the functional relationships between rap and rho modules. Arrowed lines indicate activation. Flat ending lines indicate inhibition. Circle ending lines indicate docking activity. Positive regulators of adhesion are represented as red elliptic shapes; negative regulators are in blue. Notably, although the physical and functional interactions between the different signaling molecules have been demonstrated, the functional role of these interactions in the specific context of integrin affinity regulation under experimental conditions satisfying the *four criteria* is still not always validated.](fimmu-03-00127-g002){#F2}

Is Chemokine Signaling to Integrin Affinity Modulation Universal?
=================================================================

The complexity of pro-adhesive signaling event triggered by arrest chemokines also imposes more general questions: is the mechanism of integrin affinity regulation conserved among leukocyte subpopulations? Are there universal mechanism of integrin activation or, at least, common relevant proteins activated by chemokines? Some recently published data might provide answers to these questions. For instance, PLD1 does not seem to be crucial to VLA-4 activation (Garcia-Bernal et al., [@B21]). Moreover, DOCK2 involvement in integrin activation seems cell-specific (Nombela-Arrieta et al., [@B50]). A chemokine-selective role for RhoA involvement in LFA-1 affinity regulation was also recently suggested (Pasvolsky et al., [@B51]). Furthermore, surprising data come from a recent study in B cell chronic lymphocytic leukemia (B-CLL; Montresor et al., [@B46]), a lymphoproliferative disorder characterized by accumulation of immune incompetent B-lymphocytes in the blood, bone marrow, lymph nodes and spleen. In human normal B-lymphocytes, the CXCL12-triggered rho-module of LFA-1 affinity triggering is functionally conserved, with no differences with respect to normal T lymphocytes. However, and in sharp contrast, in B-CLL cells the CXCL12-triggered rho-module of LFA-1 affinity triggering appears no longer fully operational. Specifically, RhoA and PLD1 are fully activated and involved in LFA-1 affinity regulation also in B-CLL cells. In contrast, Rac1 and CDC42 are variably involved in LFA-1 affinity modulation, depending on the studied B-CLL patients, who could be grouped in two cohorts, either showing conserved or absent regulatory role for Rac1 and CDC42 in LFA-1 affinity modulation by CXCL12. Even more surprisingly, PIP5K1C emerges as totally irrelevant to LFA-1 affinity triggering in all studied B-CLL patients. Thus, the neoplastic transformation and progression may completely bypass the role of PIP5K1C and variably affect the Rac1 and CDC42 roles. Since the capability of CXCL12 to trigger LFA-1 affinity states is always fully conserved, altogether these findings show that other proteins regulate the inside-out signaling in leukemic cells, thus highlighting the relative, not universal, nature of the rho-module. Overall, these observations show that universal signaling mechanisms of LFA-1 (and more in general integrin) affinity triggering likely do not exist. An accurate definition of these mechanisms in several different cell-, agonist-, and disease-specific experimental contexts, with particular attention to the *four criteria* proposed herein, will be mandatory to fully understand the mechanisms by which arrest chemokines regulate cell trafficking.
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